Cartalax

Mechanism of action in research models

Cartalax is used in longevity, mitochondrial, immune-modulatory, and cellular stress research programmes. Typical endpoints include mitochondrial membrane potential, ROS production, NAD+/NADH ratios, senescence-associated markers, and innate immune signalling in cell culture or animal models. Mitochondria-targeted peptides may interact with cardiolipin or inner-membrane components; thymic peptides modulate T-cell differentiation pathways in immunology research.

All HALO longevity-cluster materials are RUO reference compounds. Experimental design should separate biochemical mechanism data from any clinical extrapolation.

Research background

Longevity research increasingly relies on well-characterised peptide tool compounds with documented purity and identity. Cartalax is supplied with independent COA verification so laboratories can cite batch-specific analytical data in methods sections and procurement audits.

Documentation and COA standards

Each HALO lot of Cartalax ships with an independent certificate of analysis documenting:

• HPLC purity — reverse-phase chromatography with ≥98% main peak by area integration
• Identity confirmation — LC-MS, ESI-MS, or MALDI-TOF as applicable to molecular weight
• Lot / batch number — must match the vial label for procurement audit trails
• Test date and method — third-party laboratory, not supplier self-reporting

Read: What is a peptide COA? · Batch-specific verification · Lab results index

Storage and handling

Store lyophilized Cartalax sealed, cold (−20 °C), dry, and protected from light until reconstitution. After reconstitution with an appropriate research diluent, follow institutional stability protocols; minimise freeze-thaw cycles and document open-vial dates in the lab log.

Tools: Peptide calculator · Lyophilized peptide guide · Stability guide